EUVIMEDEUVIMED entdecken
Crossref

Preclinical Evaluation of 177 Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors

Andrea Galbiati, Matilde Bocci, Domenico Ravazza, Jacqueline Mock, Ettore Gilardoni, Dario Neri, Samuele Cazzamalli

Journal of Nuclear Medicine · 2024-10 · 65 (10) · 1604-1610

DOI: 10.2967/jnumed.124.268200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 12.09.2024. Verfasst von Andrea Galbiati und 6 weiteren Autor:innen. Beteiligte Einrichtung: R&D Department, Philochem AG, Otelfingen, Switzerland; andrea.galbiati@philochem.ch samuele.cazzamalli@philochem.ch. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Lutetium, Endopeptidases, Radioisotopes. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast activation protein (FAP) is abundantly expressed in the stroma of most human solid tumors. Clinical-stage radiolabeled FAP ligands are increasingly used as tools for the detection of various cancer lesions. To unleash the full therapeutic potential of FAP-targeting agents, ligands need to remain at the tumor site for several days after administration. We recently described the discovery of OncoFAP, a high-affinity small organic ligand of FAP with a rapid accumulation in tumors and low uptake in healthy tissues in cancer patients. Trimerization of OncoFAP provided a derivative (named TriOncoFAP, or OncoFAP-23) with improved FAP affinity. In this work, we evaluated the tissue biodistribution profile and the therapeutic performance of OncoFAP-23 in tumor-bearing mice.

Methods

OncoFAP-23 was radiolabeled with the theranostic radionuclide 177Lu. Preclinical experiments were conducted on mice bearing SK-RC-52.hFAP (BALB/c nude mice) or CT-26.hFAP (BALB/c mice) tumors. 177Lu-OncoFAP and 177Lu-FAP-2286 were included in the biodistribution study as controls. Toxicologic evaluation was performed on Wistar rats and CD1 mice by injecting high doses of OncoFAP-23 or its cold-labeled counterpart, respectively.

Results

177Lu-OncoFAP-23 emerged for its best-in-class biodistribution profile, high and prolonged tumor uptake (i.e., ∼16 percentage injected dose/g at 96 h), and low accumulation in healthy organs, which correlates well with its potent single-agent anticancer activity at low levels of administered radioactivity. Combination treatment with the tumor-targeted interleukin 2 (L19-IL2, a clinical-stage immunocytokine) further expands the therapeutic window of 177Lu-OncoFAP-23 by potentiating its in vivo antitumor activity. Proteomics studies revealed a potent tumor-directed immune response on treatment with the combination. OncoFAP-23 and natLu-OncoFAP-23 exhibited a favorable toxicologic profile, without showing any side effects or signs of toxicity.

Conclusion

OncoFAP-23 presents enhanced tumor uptake and tumor retention and low accumulation in healthy organs, findings that correspond to a strongly improved in vivo antitumor efficacy. The data presented in this work support the clinical development of 177Lu-OncoFAP-23 for the treatment of FAP-positive solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsLutetiumEndopeptidasesRadioisotopesGelatinasesMembrane ProteinsAnimalsMiceRatsHumansTissue DistributionCell Line, TumorSerine EndopeptidasesNeoplasmsFemaleMice, Inbred BALB CFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

OncoFAPfibroblast activation proteinradiopharmaceutical therapeuticsradiopharmaceuticalstargeted cancer therapytumor microenvironment

Substanzen

RadiopharmaceuticalsLutetiumEndopeptidasesRadioisotopesGelatinasesMembrane ProteinsSerine EndopeptidasesFibroblast Activation Protein AlphaLutetium-177

Autor:innen und Institutionen

  • R&D Department, Philochem AG, Otelfingen, Switzerland; andrea.galbiati@philochem.ch samuele.cazzamalli@philochem.ch.
  • R&D Department, Philochem AG, Otelfingen, Switzerland.
  • Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland; and.
  • Philogen S.p.A., Siena, Italy.

Zitieren

APA

Galbiati, A., Bocci, M., Ravazza, D., Mock, J., Gilardoni, E., Neri, D., & Cazzamalli, S. (2024). Preclinical Evaluation of 177 Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors. Journal of Nuclear Medicine, 65(10), 1604-1610. https://doi.org/10.2967/jnumed.124.268200

Vancouver

Galbiati A, Bocci M, Ravazza D, Mock J, Gilardoni E, Neri D, et al. Preclinical Evaluation of 177 Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors. Journal of Nuclear Medicine. 2024;65(10):1604-1610. doi:10.2967/jnumed.124.268200

BibTeX
@article{Galbiati2024,
  author = {Galbiati, Andrea and Bocci, Matilde and Ravazza, Domenico and Mock, Jacqueline and Gilardoni, Ettore and Neri, Dario and Cazzamalli, Samuele},
  title = {Preclinical Evaluation of 177 Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {10},
  pages = {1604--1610},
  doi = {10.2967/jnumed.124.268200}
}
Kostenlos starten →